Today, I’m so pleased to share with you some exciting news about our new partnership with JDRF, in collaboration with the Helmsley Charitable Trust (HCT), to advance the development of continuous glucose monitoring toward an artificial pancreas.
The goal of the partnership is to accelerate the development of the Medtronic novel redundant sensor system, which combines two unique sensing technologies in one device. This technology was awarded funding support from the JDRF-Helmsley Charitable Trust collaboration’s Sensor Initiative. The JDRF-HCT Sensor Initiative was launched to accelerate the development and delivery of more accurate and reliable continuous glucose sensors. Continuous glucose sensorsare the potential basis for the development of future artificial pancreas systems for people with diabetes. Today’s CGM devices have significantly helped improve glucose control in people with type 1 diabetes. We hope that next generation sensors can provide improved accuracy and reliability, and allow for more aggressive insulin management and support the development of automated artificial pancreas systems.
The orthogonally redundant sensor system will combine an electrochemical sensor (which is what is used in the CGM systems currently on the market) with an optical sensor. By combining two distinctive measurement technologies, the two sensors would function as a “check and balance” system of redundancy for glucose measurements for an artificial pancreas system.
CGM devices provide both a real-time snapshot of the glucose level of a person with diabetes, as well as trend information on whether glucose is moving upwards or downwards, and how fast. The devices also provide warnings when the glucose is becoming too high or too low. JDRF’s landmark CGM trials have shown that using CGM can significantly improve diabetes control and decrease the frequency of high and low blood sugars when used regularly. Today, these sensors are being studied as part of artificial pancreas systems, in the hopes of reducing the amount of high and low blood sugar people with diabetes experience by automating insulin delivery some of the time. To reach the next stage after that, artificial pancreas systems that can restore non-diabetes like glucose levels and are automated most of the time will require advanced sensors with increased accuracy and error detection capabilities.
On Tuesday, June 5 we will be hosting a Web cast with the JDRF and the Helmsley Charitable Trust for the diabetes community at 12:30 pm PT/3:30 pm ET. To register, please visit: http://engage.vevent.com/index.jsp?eid=1464&seid=12
Along with the rest of my colleagues here at Medtronic, I’m thrilled about accelerating the development of this technology in our drive toward an artificial pancreas. And, of course, we’re all very excited to be teaming up with JDRF once again. If you have any questions about the partnership, let us know in the comments!
 Bergenstal RM, Tamborlane WV, Ahmann A, et al; the STAR 3 Study Group. Effectiveness of sensor augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-320.
 The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose
IMPORTANT SAFETY INFORMATION
– Medtronic Diabetes insulin infusion pumps, continuous glucose monitoring systems and associated components are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks associated with the use of these systems.
– Successful operation of the insulin infusion pumps and/or continuous glucose monitoring systems requires adequate vision and hearing to recognize alerts and alarms.
Medtronic Diabetes Insulin Infusion Pumps
– Insulin pump therapy is not recommended for individuals who are unable or unwilling to perform a minimum of four blood glucose tests per day.
– Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately.
Medtronic Diabetes Continuous Glucose Monitoring (CGM) Systems
– The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a home glucose meter. A confirmatory fingerstick is required prior to treatment.
– Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected.
Please visit MedtronicDiabetes.com/isi for complete safety information.
Tags: artificial pancreas
, continuous glucose monitoring
, product development